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Abstract
Background: In this multi-centre randomized controlled trial (RCT) we compared modified mentalisation-based
treatment (MBT-ED) to specialist supportive clinical management (SSCM-ED) in patients with eating disorders (EDs)
and borderline personality disorder symptoms (BPD). This group of patients presents complex challenges to clinical
services, and a treatment which addresses their multiple problems has the potential to improve outcome. MBT has been
shown to be effective in improving outcome in patients with BPD, but its use has not been reported in ED.
Methods: Sixty-eight eligible participants were randomised to MBT-ED or SSCM-ED. The primary outcome measure was
the global score on the Eating Disorder Examination. Secondary outcomes included measures of BPD symptoms (the
Zanarini Rating Scale for Borderline Personality Disorder), general psychiatric state, quality of life and service utilisation.
Participants were assessed at baseline and at 6, 12 and 18 months after randomisation. Analysis was performed using
linear mixed models.
Results: Only 15 participants (22 %) completed the 18 month follow-up. Early drop-out occurred significantly more in the
SSCM-ED group. Drop-out did not vary with treatment model later in therapy and was sometimes attributed
to participants moving away. There was higher drop–out amongst smokers and those with higher neuroticism
scores. 47.1 % of participants in the MBT-ED arm and 37.1 % in the SSCM-ED arm attended at least 50 % of
therapy sessions offered.
Amongst those remaining in the trial, at 12 and 18 months MBT-ED was associated with a greater reduction in Shape
Concern and Weight Concern in the Eating Disorder Examination compared to SSCM-ED. At 6, 12 and 18 months there
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was a decline of ED and BPD symptoms in both groups combined.
Ten participants were reported as having had adverse events during the trial, mostly self-harm, and there was one
death, attributed as ’unexplained’ by the coroner.
Conclusions: The high drop-out rate made interpretation of the results difficult. Greater involvement of research staff
in clinical management might have improved compliance with both therapy and research assessment. MBT-ED may
have had an impact on core body image psychopathology.
Trial registration: Current Controlled Trials: ISRCTN51304415. Registered on 19 April 2011.
Keywords: Eating disorders, Psychotherapy, Borderline personality disorder, Mentalisation-based treatment, Specialist
supportive clinical management, Randomised controlled trial, Drop-out
Background
Patients with eating disorders (EDs) and co-occurring
symptoms of borderline personality disorder (BPD)
present considerable clinical challenges. Their eating dis-
order is associated with self-harm, impulsivity, physical
problems, substance abuse and ambivalence about treat-
ment. Their complex natural history, with migration
from one ED to another [1], means they are often
referred to different units, one to manage their eating
and weight disorder, another to treat their impulsivity
and self-harm and yet another to manage comorbid sub-
stance misuse. In an attempt to focus treatment, an inte-
grated model of care was developed. We chose to
compare mentalisation-based treatment (MBT), which
has proved efficacious with patients with BPD [2], with
specialist supportive clinical management (SSCM),
which has been used with benefit in trials of therapy for
anorexia nervosa [3]. We chose MBT on the basis that
behaviours associated with EDs, including problems with
body image, impulsivity and self-harm, are all symptoms
related to vulnerabilities to loss of mentalising. More-
over, MBT is particularly appropriate for testing in
eating disordered patients because the latter have been
shown to have several features linked to mentalising
function, including attachment insecurity [4], problems
with emotion regulation [5, 6], disturbances of emotional
theory of mind (eTOM) in anorexia nervosa, including
recovered patients [7], and unusually distributed menta-
lising function in bulimia nervosa [8].
Because MBT has not been reported in studies of
patients with EDs and because SSCM is designed for
patients with anorexia nervosa only, we needed to modify
MBT so that it was relevant to participants with EDs, and
SSCM so that it could be applied to all EDs. We called the
two modified therapies MBT-ED and SSCM-ED.
Our primary objective was to evaluate whether MBT
is clinically effective in reducing observer rated symp-
toms of ED, using an accepted measure, the Eating
Disorder Examination, in patients with combined eating
and borderline personality disorder symptoms up to
18 months post randomisation compared to SSCM.
Secondary objectives included evaluation of the same
therapy in reducing symptoms of BPD using a standard
assessment [9] and evaluating the health economic im-
plications of the therapy. The full protocol for the study
has been published [10].
Recruitment into NOURISHED (Nice OUtcomes for
Referrals with Impulsivity, Self Harm and Eating Disor-
ders) was difficult, and maintenance of patients in long-
term treatment and follow-up proved problematic. We
therefore aim to describe the patterns of recruitment and
follow-up, providing estimates of effect size at the follow-
up assessments, and to discuss the challenges of this trial.
Methods
Study design
This multi-centre study ran across five clinical centres:
three NHS Eating Disorder Units and two NHS Person-
ality Disorder Units, located in four clinical sites, three
in London, UK and one in Maidstone, Kent, UK.
The design is a single-blind (researchers and statisti-
cians are blind) randomised controlled trial of MBT-ED.
MBT-ED consisted of one individual and one group
session per week for one year. SSCM-ED comprised one
session every 1–4 weeks for 20 to 26 sessions over one
year. All trial participants had access to 5 hours of
dietetic advice over the course of treatment.
All participants were asked to complete a battery of
questionnaires at assessment and at 6, 12 and 18 months
follow-up. Because of high drop-out, a further postal
assessment was done at 36 months.
Participants
Patients were considered for participation if they were:
1. Aged 18 years or older
2. Had a Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV [11] diagnosis of an eating
disorder
3. Fulfilled either DSM-IV criteria [11] for BPD or had
’BPD symptoms’. The criteria for BPD symptoms
were both of the behavioural criteria of DSM-IV:
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(a) Impulsivity in at least two areas that are potentially
self-damaging (e.g. spending, sexual behaviour, sub-
stance abuse, reckless driving, binge eating)
(b)Recurrent suicidal behaviour or self-mutilating
behaviour.
Exclusion criteria were current psychosis based on the
Mini International Neuropsychiatric Schedule (MINI)
examination, current inpatient or day-patient (attending
3 or more days per week), currently in individual or group
psychological therapy, received MBT less than 6 months
prior to randomisation, organic brain disease leading to
significant cognitive impairment or body mass index
(BMI) less than 15 kg/m2 (normal range is 18.5–25).
Recruitment and consent
Participants were recruited from the clinical centres by
referral from doctors working in the outpatient services
of each centre. Referrals were received by the trial man-
ager, who contacted the potential participant, provided
the Participant Information Sheet and then instructed a
research assistant to arrange a meeting with the poten-
tial participant, obtain informed consent and conduct
the initial assessment. All eligible patients were asked to
consider participating in the trial, and consent was ob-
tained at least 24 hours after the patient was given the
Participant Information Sheet.
Assessments
Outcome measures were collected pre randomisation
(baseline) and at 6, 12 and 18 months post randomisation.
The primary outcome was the global score on the Eating
Disorder Examination (EDE) at 18 months. The EDE
assesses eating disorder psychopathology [12]. It is rated
through the use of four subscales (Restraint, Eating, Shape
Concern and Weight Concern) and a global score (0–41).
Higher scores indicate a greater level of symptomatology.
Other measures used are described as follows:
 The Mini International Neuropsychiatric Schedule
(MINI) [13] is a short structured clinical interview
for diagnoses of psychiatric disorders according to
DSM-IV or International Classification of Diseases
(ICD)-10.
 Structured Clinical Interviews for DSM-IV (SCID I,
SCID II) are diagnostic instruments used to assess
for the presence of Axis I, mental disorders, and
Axis II, personality disorders [14].
 Global Assessment of Functioning (GAF) [15] is a
numerical scale (1 to 100) used to rate social,
occupational and psychological functioning. A higher
score is associated with fewer symptoms. The GAF
has adequate inter-rater reliability (intraclass
correlation 0.81 [15]).
 The Zanarini Rating Scale for Borderline Personality
Disorder (ZAN-BPD) [9] is a continuous measure
for assessment of DSM-IV borderline psychopath-
ology. Each of the nine criteria for BPD is rated by a
trained observer on a 5-point anchored rating scale
of 0 to 4, yielding a total score of 0 to 36.
 EuroQol-5D (EQ-5D) is a standardized instrument
for use as a measure of health outcome [16].
 General psychopathology was assessed using the
Depression, Anxiety, Stress Scale-21 (DASS-21) [17],
a 21-item self-report measure that assesses mood
state over the past 7 days using a 4-point Likert
scale. The total scale is used as a measure of distress;
higher scores indicate more symptomatology.
 The Adult Service Use Schedule (AD-SUS) [18] is
an interview which was administered by a research
worker, covering employment and use of hospital
and community services.
 The Big Five Inventory (BFI) [19] is a self-rated,
46-item questionnaire which yields five subscores
for personality dimensions: Extraversion, Agreeable-
ness, Conscientiousness, Neuroticism and Openness.
Apart from the MINI and the SCID II, which were
only administered at baseline for diagnostic purposes, all
instruments were repeated at 6, 12 and 18 months post
randomisation.
As the majority of participants were in the normal
weight range, we chose not to include body weight or
BMI in outcome measures.
Because attendance for follow-up interviews at 18 months
was poor (15 out of the original 68), we decided to do a
postal questionnaire follow-up at an average of 36 months
after randomisation, offering a small financial incentive to
participants returning the completed questionnaires. The
questionnaires completed at 36 months were the EDE-Q,
the DASS and the GAF.
Safety monitoring
The safety of patients, particularly in view of the possi-
bility of self-harm and physical problems due to the
eating disorder, was assured by research and clinical staff
at the participating research sites.
Randomisation, allocation concealment and protection
against bias
Due to the nature of the intervention, blinding of partic-
ipants and therapists was not possible. However, the trial
statistician and research workers responsible for the col-
lection of the assessments remained blind to treatment
allocation during the trial and primary analyses. At every
meeting with participants, research workers reminded
them that they were not allowed to know which treat-
ment the participants had received.
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Following completion of the baseline questionnaire,
patients who consented to take part in the trial were
randomly allocated to MBT-ED or SSCM-ED (ratio 1:1)
by site via an on-line system based at the King’s College
London Clinical Trials Unit, at the Institute of Psychiatry,
Psychology and Neuroscience in London. The method of
randomisation of participants was block randomisation
stratified by BMI (15.0–18.5, 18.6–24.9, >25). Randomly
varying block sizes were implemented in order to main-
tain pre randomisation allocation concealment. The trial
manager used the randomisation result to allocate partici-
pants to a treatment.
Intervention
Experimental condition: mentalisation-based treatment
(MBT-ED)
This treatment was based on the Intensive Outpatient
Therapy model [2]. The therapist provided a weekly 50-
minute individual MBT-ED session. Participants also
attended weekly group MBT-ED for 90 minutes with
one or two therapists and four to six patients. Therapy
lasted for 12 months, after which patients were reas-
sessed by a member of the trial clinical team and
referred for further management if required. Participants
assigned to MBT-ED were offered 44 individual sessions
and 44 group sessions over the course of 12 months.
Thus, the total number of hours offered was 102.7 hours
over 12 months.
The Chief Investigator (PR) wrote a manual for the
treatment of patients with EDs and BPD using as a basis
the already published description of MBT [20]. This ap-
proach, MBT-ED, has been summarised [21].
Control condition: specialist supportive clinical
management for eating disorders (SSCM-ED)
This therapy was based on SSCM as described by
McIntosh et al. [3]. SSCM was designed for patients with
a diagnosis of anorexia nervosa and has been used in
several trials for this patient group [3, 22, 23]. We
decided to use SSCM as the basis for the treatment of any
eating disorder, reasoning that the key symptoms of EDs
in general (namely food restriction, body image disturb-
ance, binge eating, vomiting and laxative abuse) all occur
in anorexia nervosa, for which SSCM was designed. We
therefore developed an extended form of SSCM and called
it SSCM-ED. With the collaboration of Dr McIntosh and
Professor Bulik, the SSCM manual was adapted to address
other EDs, i.e. ’bulimia nervosa’, ’binge eating disorder’ and
’eating disorder not otherwise specified’. The basic format
of SSCM was retained, and this approach includes many of
the behavioural elements of cognitive behavioural therapy
for eating disorders [24]. Therapists were told that therapy
sessions could be curtailed after 30 minutes if appropriate.
However, in practice, SSCM-ED sessions lasted 60 minutes.
The total number of sessions was 20, with a possibility of
up to 6 more sessions at the end if patient, therapist and
supervisor agreed. Thus, the total therapy time offered was
between 20 and 26 hours over 12 months.
Users’ involvement
Two service user consultants (SUCs) and one carer con-
sultant (CC) were recruited to help with the trial. They
contributed to the writing of documents such as patient
and carer information leaflets and user satisfaction ques-
tionnaires, they acted as interviewers on appointment
committees and attended telephone conferences for the
Trial Steering Committee (TSC). Their contribution was
highly valued by the Chief Investigator and other mem-
bers of the trial team, including the Chair of the TSC.
Their hours and transport were paid. In their feedback
they suggested that SUCs and CCs should be involved
more in future trials.
Adherence to treatment model
Adherence to the treatment model was tested by the su-
pervisors. After the trial, seven recorded and transcribed
sessions each of MBT-ED (individual therapy, four ther-
apists) and SSCM-ED (seven therapists) were randomly
selected and subjected to adherence rating. For MBT-ED
a trained research assistant (AR) rated the sessions using
the MBT Adherence and Competence Scale (MBT-ACS)
[25] with a 7-point scale in which 4 represents adequate
therapy. The transcriptions were rescored by an experi-
enced rater (FS) whose adjustments were accepted.
There is no published adherence scale for SSCM. PR
developed an approach which counts the number of times
a therapist followed the manual and the number of times
the therapist did not follow the manual. This led to an
overall score of adherence, using a 7-point scale as in the
MBT-ACS, with a score of 4 representing adequate
therapy. Seven randomly chosen transcripts were scored
by an independent observer (AR), and the transcripts were
read and rescored by a senior author (PR).
Statistical analysis
Power calculation
The sample size calculation was based on the mean dif-
ference in global EDE scores at 18 months post random-
isation. We utilised an effect size of 1.07 based on a
minimal clinically important difference of 1.5 points with
a pooled standard deviation of 1.4. An overall sample
size of 140 would provide more than 90 % power to
detect an effect size of d = 1.07 using an analysis of
covariance with two-sided 5 % significance tests. This
calculation included inflation for 25 % attrition; made
the conservative assumption of no correlation between
baseline and follow-up; and allowed for clustering of
group treatment in the MBT-ED arm. We assumed an
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average group size of 10 and an intraclass correlation be-
tween EDE scores of 0.07, which resulted in a design ef-
fect of 1.63.
Analysis
The statistical analysis plan was finalised and approved
by the TSC. A value of p < 0.05 was regarded as signifi-
cant for all analyses and based on the intention-to-treat
sample. We summarised continuous variables as mean
(SD) and categorical variables as n (%). Unadjusted effect
sizes (Cohen’s d) were calculated at 6, 12 and 18 months
post randomisation for all outcomes. Not all question-
naires and interviews anticipated in the protocol [10]
were included in this analysis. Some were excluded be-
cause the small numbers remaining at follow-up did not
justify statistical analysis of outcome over time, and
others (the Object Relations Inventory (ORI), treatment
adherence, Reading the Mind in the Eyes test and the
Reflective Functioning Questionnaire (RFQ)) will be de-
scribed elsewhere (for references see [10]).
EDE and ZAN-BPD outcomes were analysed using lin-
ear mixed models. The dependent variable was the out-
come, with trial arm, baseline value of the variable
under investigation, randomisation stratifier (BMI) and
time (6, 12, 18 and 36 months where available) as covari-
ates. We included a time by treatment interaction term
to allow estimates at the individual time points to be
summarised.
The models incorporated random intercepts for partic-
ipants and an additional random effect for therapists.
This allowed for correlations in outcomes related to
treatment from repeated measures from the same indi-
vidual and by therapist, respectively.
Model assumptions were checked by use of diagnostic
plots. Due to the small number of follow-up measures,
the stability of significant results was checked by bias
corrected confidence intervals, bootstrapped with 1000
repetitions. We did modelling with the assumption that
data were missing at random, and included predictors of
missing data (neuroticism and smoking status) in the
modelling. We used a logistic model to assess predictors
of missing data (examination of all baseline clinical and
demographic variables). Due to the low number of
follow-up assessments, no moderation or mediation
analyses were completed.
We completed exploratory pre/post analyses also
utilising linear mixed modelling. Assessments at baseline
were included as part of the outcome, and time as a co-
variate included 0 (baseline) to allow estimates of change
to be summarised in the treatment groups and overall.
We summarised results from the main outcomes EDE
and ZAN-BPD at 6, 12, 18 and 36 months post random-
isation with two-sided 95 % CIs. All analyses were done
with Stata version 13.0 [26].
Economic evaluation
The economic evaluation took a National Health Service
(NHS)/Personal Social Services (PSS) perspective as rec-
ommended by the National Institute for Health and Care
Excellence (NICE), including the cost of all hospital and
community health and social care services. Resource use
information was collected using a modified version of
the Adult Service Use Schedule (AD-SUS). Resource use
data were combined with appropriate national unit costs
to calculate the total cost of the intervention and control
groups. The costs of the MBT-ED were directly calcu-
lated from salaries using a microcosting approach [27].
Differences in mean total costs between groups were
compared using the standard t test with ordinary least
squares regression used for adjusted analyses and the
validity of results confirmed using bootstrapping [28].
Results
Results relevant to the conduct of the trial
Recruitment of participants
The power calculation indicated that 140 participants
would be required in total. Recruitment, which occurred
between July 2011 and November 2012, was brisk at the
beginning and then flattened while the recruited partici-
pants were treated. Recruitment picked up again when a
new cohort of participants could be treated. The length
of the study was dictated by the funding available.
The factors which affected recruitment were (1) delays
in recruiting research workers due to funding restric-
tions, (2) availability of trained therapists, especially for
MBT-ED, and (3) agreement of patients to participate in
the study.
During the two-and-a-half-year recruitment period, a
total of 135 patients were screened for eligibility, and 68
participants were randomised in the trial. Reasons for in-
eligibility are given in Fig. 1.
Baseline data
Demographics
Demographics and clinical characteristics are summarised
in Table 1. In particular, our participant population was
92.7 % female, reflecting gender differences in attendance
of eating disorder clinics reported elsewhere [29].
The proportion of participants from ethnic minorities
was less than expected (14.7 %) considering that, for
London boroughs local to the main recruitment site,
census data [30] suggest some 42 % of residents are of
non-White ethnicity. The two treatment arms were rea-
sonably balanced on all baseline characteristics.
Clinical information
General ability to function, as measured by the GAF, was
affected in all but one participant to at least a moderate
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extent; 57.4 % of participants showed at least ’serious’
impairment on the scale.
The MINI [13] revealed a broad range of psychiatric
disorders with 88.2 % fulfilling criteria for affective
disorder and 93.3 % assessed as having a high risk of
suicide. The SCID-II showed that 92.1 % of the participants
fulfilled criteria for a personality disorder: 76 % had BPD
and 16 % depressive or avoidant PD. The mean scores on
the DASS in our patients were all in the Extremely Severe
ranges, which are more than 14 for depression, more than
10 for anxiety and more than 17 for stress.
In summary, the 68 participants recruited for the
NOURISHED study had very high scores on measures of
eating disorder, general psychiatric symptoms and BPD
descriptive criteria. They mostly suffered from bulimia
nervosa (BN) or eating disorder not otherwise specified
(EDNOS), and most had BPD. None of the diagnoses
was significantly more represented in one treatment
condition compared to another.
Only 7 patients had a BMI less than 18.5, and in 6
participants the BMI was more than 30, leaving the majority,
55 participants, in the range 18.5–30.
Fig. 1 Consolidated Standards Of Reporting Trials (CONSORT) diagram showing the participants remaining at each stage of the trial
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Treatment information
Therapy training and supervision
MBT-ED therapists in the study fulfilled the following
criteria. (1) They had received basic mental health train-
ing (such as Mental Health Nursing, Psychotherapy,
Psychiatry, Clinical Psychology or Occupational Therapy).
(2) They had completed a recognised basic training in
MBT. (3) They had attended a one-day MBT-ED course
provided by senior members of the research team
(Prof AB, PR). (4) They had treated a patient with
MBT or co-run an MBT group under qualified super-
vision for at least 6 months. During the trial, thera-
pists provided recordings of group and individual
MBT-ED sessions and attended regular supervision,
including review of the recordings.
SSCM-ED
Staff wishing to provide SSCM-ED as part of the
NOURISHED study needed to fulfil the following
criteria: (1) working in a post in which patients with
EDs form a substantial part of the caseload, (2) having
worked with patients with EDs for at least 6 months, (3)
having attended a one-day training in SSCM-ED by a
senior member of the research team (PR), (4) attend-
ing supervision by an experienced supervisor at least
monthly, providing session recordings, (5) providing
random session recordings to be reviewed by an
experienced supervisor. During the trial, as for MBT-ED,
regular supervision was attended and therapy recordings
provided.
The two trial therapies were set up at all four
research sites together with supervision, according to
the protocol. Therapy provision presented significant
challenges. The need for training and experience delayed
recruitment of therapists, particularly for MBT-ED. There
was significant staff turnover amongst therapists, two
Principal Investigators left their posts and clinical services
were altered by management, compromising provision of
trial interventions. Three MBT-ED therapists and three
SSCM-ED therapists (out of 28 therapists in total) left
their posts before therapy with their patients had ended.
The resulting delays and disruptions accounted for much
of the shortfall in recruitment and in retention within
therapy.
Table 1 Baseline characteristics of the sample
MBT-ED SSCM-ED Total
(N = 34) (N = 34) (N = 68)
Demographics Age, years (mean [SD]) 31.2 (9.8) 30.8 (10.0) 31.1 (9.9)
Gender, female (n [%]) 32 (94.1 %) 31 (91.2 %) 63 (92.7 %)
Ethnicity, white (n [%]) 28 (82.4 %) 29 (85.3 %) 57 (83.8 %)
Ever smoked (n [%]) 22 (64.7 %) 25 (73.5 %) 47 (69.1 %)
Years in education (mean [SD]) 19.9 (3.5) 19.0 (3.0) 19.4 (3.3)
Clinical Weight (kg) (mean [SD]) 69.41 (28.2) 63.16 (13.4) 66.23 (22.0)
BMI (mean, SD) 25.4 (11.4) 22.9 (4.5) 24.1 (8.6)
BMI 15–18.5 (n [%]) 6 (17.7 %) 5 (14.7 %) 11 (16.2 %)
BMI 18.6–24.9 (n [%]) 18 (52.9 %) 18 (52.9 %) 36 (52.9 %)
BMI >25 (n [%]) 10 (29.4 %) 11 (32.4 %) 21 (30.9 %)
Diagnosis anorexia nervosa (n [%]) 2 (5.9 %) 2 (5.9 %) 4 (5.9 %)
Diagnosis bulimia nervosa (n [%]) 22 (64.7 %) 21 (61.8 %) 43 (63.2 %)
Diagnosis binge eating disorder (n [%]) 2 (5.9 %) - 2 (2.9 %)
Diagnosis EDNOS (n [%]) 8 (23.5 %) 11 (32.4 %) 19 (27.9 %)
EDE global (mean [SD]) 4.40 (1.0) 4.23 (0.8) 4.31 (0.9)
EDE Eating Concern (mean [SD]) 3.54 (1.21) 3.47 (1.14) 3.51 (1.17)
EDE Shape Concern (mean [SD]) 5.09 (0.92) 4.83 (0.92) 4.96 (0.92)
EDE Weight Concern (mean [SD]) 4.71 (1.19) 4.56 (1.36) 4.64 (1.27)
ZAN-BPD (mean [SD]) 16.12 (6.3) 16.74 (6.0) 16.43 (6.1)
DASS-21 (mean [SD]) 26.3 (8.3) 29.18 (9.1) 27.76 (8.8)
EuroQol VAS (mean [SD])a 48.09 (20.9) 50.56 (19.9) 49.32 (20.3)
GAF (mean [SD])a 47.32 (6.3) 49.12 (6.5) 48.22 (6.4)
BMI body mass index, EDNOS eating disorder not otherwise specified, EDE Eating Disorder Examination, DASS-21 Depression, Anxiety, Stress Scale, GAF Global
Assessment of Functioning, ZAN-BPD Zanarini Rating Scale for Borderline Personality Disorder
aIndicates a higher value is a better outcome
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Treatment compliance and drop-out from therapy
Twenty participants dropped out before attending any
sessions; a further 18 dropped out after beginning ther-
apy. Twenty-nine participants dropped out after attend-
ing less than 50 % of sessions offered, and 8 dropped out
after attending more than 50 %.
We set a level of 50 % attendance [10] to indicate
compliance. That level was achieved by 47.1 % in the
MBT-ED arm and 37.1 % in the SSCM-ED arm. The
compliance with research assessment follow-up is pre-
sented in the CONSORT diagram (Fig. 1).
We analysed the baseline data for factors that might
predict drop-out. Only two factors emerged: Neuroticism
on the Big Five Inventory of Personality [19] and smoking
status, current smokers being more likely to drop out of
the study. Neuroticism was entered into a correlation
matrix (Pearson’s r) and correlated positively with the
Stress and Anxiety scales of the DASS (r = 0.54, p = 0.000,
r = 0.47, p = 0.000) and negatively with the measures of
quality of life (Physical r = −0.48, p = 0.000, Psychological
r = 0.34, p = 0.004) [16]. Of those participants allocated to
SSCM-ED, more (15 participants, 44 %) failed to start
treatment compared to those allocated to MBT-ED (5
participants, 15 %). This difference is significant (chi-
squared = 7.08, p = 0.008, Fisher’s exact test: p = 0.015).
Reasons given for dropping out of therapy
Of the 53 participants who dropped out by 18 months,
reasons were provided by 32 and a further 7 did not
respond to repeated offers of therapy appointments. One
participant died. Five participants randomised to MBT-
ED cited therapy-related reasons for dropping out, com-
pared to 9 randomised to SSCM-ED. Reasons included
disappointment at being randomised to either MBT-ED
or SSCM-ED (with no difference between the therapies);
distress over having to wait for therapy; feeling that the
therapy was not helping. Fourteen participants (9 MBT-
ED and 5 SSCM-ED) had moved away or were unable to
attend due to work commitments. There was no signifi-
cant difference in reasons for drop-out between therap-
ies and no significant difference in drop-out rate
between the four clinical sites.
Adherence with treatment model
For MBT-ED, reports from all supervisors were satisfac-
tory. This was supported by the results of the MBT-ACS
used in seven randomly selected individual sessions. The
adherence scores (with number of sessions scoring that
level in brackets) were 7 (1), 6 (3), 4 (3). Competence
scores were identical to adherence scores. Karterud et al.
[25] give a rating of 4 as acceptable for MBT therapists.
For SSCM-ED, reports from supervisors were also
satisfactory. The agreed SSCM-ED adherence scale
results on seven randomly selected sessions (seven dif-
ferent therapists) were adherence 7 (2), 6 (1), 5 (1), 4 (3).
Adverse events during the trial
Ten participants were reported as having had adverse
events during the trial, including one death, in a patient
receiving MBT-ED. One participant had multiple events,
including self-harm and suicidal threats.
All events were followed up by the Chief Investigator
and reported to the Trial Oversight Committees. Internal
and external investigations into the death found no evi-
dence of any act or omission on the part of the treatment
team which would have directly caused or contributed to
her death, and the final verdict of the coroner was ’Unex-
plained Sudden Adult Death’.
Drop-out from research assessments
The CONSORT diagram (Fig. 1) demonstrates the very
high level of drop-out from follow-up assessment seen
in this study. Research workers were unable to contact
four participants, and some (15 %) had moved away. For
others, the participant would agree to attend the 4-hour
reassessment and then not appear, sometimes failing to
attend a subsequent appointment that was offered.
Research workers and the Chief Investigator used every
possible medium to contact participants. In the final
year of the study, some questionnaires were omitted, re-
ducing the time of the assessment to 1–2 hours, but this
did not seem to affect attendance. At 36 months, partici-
pants were sent an envelope of questionnaires as a long-
term follow-up assessment and offered a £10 voucher
for returning them, as well as the chance of winning a
£200 prize. Only 19 participants returned their question-
naires. The numbers shown in Fig. 1 demonstrate no
statistical difference in drop-out from research assess-
ments between the two arms of the study.
Baseline variables that showed association with miss-
ing data at the follow-up assessments were neuroticism
and smoking behaviours. High scoring neuroticism and
smoking may be associated with higher anxiety, and
more anxious participants may have found the trial too
stressful. We also found evidence that higher baseline
BMI is associated with higher levels of drop-out.
Results relevant to testing the research hypotheses
Treatment outcomes
Table 2 shows the results of the mixed modelling
adjusted for baseline score, BMI and predictors of
missingness. All data up to 36 month outcomes were
included in the modelling. Due to the small sample sizes
involved in these analyses, all inference estimates must
be interpreted as exploratory.
In terms of the primary outcome, treatment differ-
ences indicated that while there was no significant
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Table 2 Outcomes for the EDE scales and ZAN-BPD global
Outcome 6 months 12 months 18 months 36 months
MBT-ED SSCM-ED MBT-ED SSCM-ED MBT-ED SSCM-ED MBT-ED SSCM-ED
(n = 21) (n = 20) (n = 12) (n = 11) (n = 10) (n = 5) (n = 10) (n = 9)
Summaries (Mean [SD])
EDE global 3.86 (1.34) 4.12 (0.95) 3.75 (1.81) 3.78 (0.95) 3.35 (1.80) 3.73 (1.35) 3.76 (1.54) 4.13 (1.15)
EDE Eating Concern 3.09 (1.55) 3.28 (1.63) 3.22 (1.88) 2.45 (1.44) 2.78 (2.02) 3.08 (1.75) 3.11 (1.69) 3.23 (1.67)
EDE Shape Concern 4.50 (1.28) 4.77 (0.96) 4.37 (1.84) 4.95 (0.65) 3.81 (1.85) 4.78 (0.90) 4.34 (1.54) 4.88 (0.97)
EDE Weight Concern 4.46 (1.27) 4.58 (1.09) 3.99 (2.03) 4.76 (0.70) 3.72 (1.82) 4.76 (0.99) 4.17 (1.60) 4.74 (1.04)
EDE restraint 3.38 (1.79) 3.84 (1.00) 3.44 (2.14) 2.95 (1.75) 3.08 (2.40) 2.32 (2.20) 3.42 (1.99) 3.64 (1.68)
ZAN-BPD global 11.76 (7.42) 13.25 (8.69) 9.64 (7.41) 9.27 (7.39) 7.1 (6.19) 10 (7.97)
Inference Mean difference
from SSCM
p value Mean difference
from SSCM
p value Mean difference
from SSCM
p value Mean difference
from SSCM
p value
(SE) (95 % CI) (SE) (95 % CI) (SE) (95 % CI) (SE) (95 % CI)
EDE global −0.35 (−0.34) 0.31 (−1.02 to 0.33) −0.43 (−0.31) 0.16 (−1.03 to 0.17) −0.51 (−0.31) 0.10 (−1.12 to 0.10) −0.75 (−0.53) 0.16 (−1.79 to 0.29)
EDE Eating Concern −0.02 (−0.36) 0.97 (−0.79 to 0.76) −0.10 (−0.36) 0.78 (−0.80 to 0.60) −0.19 (−0.36) 0.61 (−0.90 to 0.52) −0.44 (−0.57) 0.44 (−1.56 to 0.68)
EDE Shape Concern −0.67 (−0.34) 0.05 (−1.33 to 0.01) −0.66 (−0.30) 0.03 (−1.25 to −0.07) −0.66 (−0.30) 0.03 (−1.25 to − 0.07) −0.64 (−0.51) 0.20 (−1.64 to 0.35)
EDE Weight Concern −0.47 (−0.35) 0.18 (−1.17 to 0.22) −0.56 (−0.32) 0.07 (−1.19 to 0.05) −0.66 (−0.32) 0.04 (−1.29 to − 0.04) −0.95 (−0.52) 0.07 (−1.96 to 0.06)
EDE restraint −0.26 (−0.49) 0.60 (−1.22 to 0.70) −0.36 (−0.43) 0.41 (−1.20 to 0.48) −0.45 (−0.44) 0.30 (−1.31 to 0.40) −0.75 (−0.76) 0.33 (−2.24 to 0.75)
ZAN-BPD global −2.41 (−1.87) 0.20 (−6.07 to 1.25) −2.50 (−1.84) 0.18 (−6.11 to 1.11) −2.59 (−2.49) 0.30 (−7.47 to 2.29)
Comparisons of the differences were made at 6, 12, 18 and 36 months from the final adjusted linear mixed model
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difference between the two interventions in global EDE
score, two of the subscales showed evidence of signifi-
cantly lower scores in the MBT-ED group at 12 and
18 months. These were, at 18 months, Shape Concern
(adjusted mean difference = −0.7, p = 0.029, 95 % CI =
−1.25 to −0.07) and Weight Concern (adjusted mean
difference = −0.7, p = 0.037, 95 % CI = −1.29 to −0.04).
The global ZAN-BPD score did not differ significantly
between groups at either 6 (p = 0.198), 12 (p = 0.175) or
18 (p = 0.298) months.
There were no significant effects of treatment on any
of the EDE subscales at 36 months. Additional file 1:
Figure S1 shows the treatment profile plots over the
course of the NOURISHED study for the EDE and
ZAN-BPD scales.
Standardised effect sizes
Table 3 shows the unadjusted effect sizes and 95 % con-
fidence intervals for the trial outcomes. The largest stan-
dardised effect sizes were seen at 18 months for the EDE
and ZAN-BPD scales, ranging from Cohen’s d = −0.16
(95 % CI −1.23 to 0.92) for EDE Eating Concern to
−0.60 (95 % CI −1.68 to 0.51) for EDE Shape Concern.
However measures of functioning and quality of life
showed the largest difference at 12 months. The confi-
dence intervals indicate the variability in the data from
the small sample sizes.
Exploratory changes over time
Linear mixed models including the baseline assessments
as part of the dependent variable were used to evaluate
changes in the scores over the course of the study
within trial arms. There was evidence of improve-
ments in EDE global scores at 6, 12 and 18 months
from baseline in the MBT-ED trial arm. At 18 months,
MBT-ED showed a −1.2 point reduction from baseline
(95 % CI −1.81 to −0.56, p < 0.001). However, the SSCM-
ED showed less improvement on the global scale
(18 month change from baseline −0.5, 95 % CI −1.38 to
0.29, p = 0.200).
This trend did not extend to the 36 month time
point for either treatment. Profile plots show a slight
increase in EDE scores at 36 months. Please note the
low sample size (n = 19) at this time point and probable
reporting bias.
An examination of the whole group, irrespective of
treatment, showed that global EDE score, Shape Con-
cern and Weight Concern reduced up to the 18 month
point, but not beyond (Fig. 2).
There was a fall in global ZAN-BPD scale for both
trial arms at 6, 12 and 18 months. The largest decrease
was seen again at 18 months: MBT-ED mean change
from baseline −8.8 (95 % CI −12.68 to −4.95, p < 0.001),
SSCM-ED mean change −7.5 (95 % CI −12.49 to
−2.55, p = 0.003).
Table 3 Unadjusted effect sizes between MBT-ED and SSCM-ED with 95 % confidence intervals
6 months 12 months 18 months
Cohen’s d (95 % CI) Cohen’s d (95 % CI) Cohen’s d (95 % CI)
Eating Disorder Examination
Eating Concern −0.12 (−0.74 to 0.49) 0.45 (−0.36 to 1.24) −0.16 (−1.23 to 0.92)
Shape Concern −0.24 (−0.85 to 0.38) −0.40 (−1.20 to 0.40) −0.60 (−1.68 to 0.51)
Weight Concern −0.10 (−0.72 to 0.51) −0.49 (−1.29 to 0.32) −0.65 (−1.74 to 0.47)
Restraint −0.31 (−0.93 to 0.31) 0.25 (−0.55 to 1.04) 0.33 (−0.76 to 1.40)
Global −0.22 (−0.84 to 0.39) −0.02 (−0.81 to 0.77) −0.23 (−1.30 to 0.85)
Zanarini Scale
Global score −0.19 (−0.78 to 0.43) 0.05 (−0.74 to 0.84) −0.43 (−1.51 to 0.67)
Depression Anxiety Stress Scale
Stress −0.78 (−1.41 to − 0.14) −0.21 (−1.02 to 0.62) −0.11 (−1.20 to 0.99)
Anxiety −0.07 (−0.69 to 0.56) 0.26 (−0.54 to 1.05) −0.04 (−1.13 to 1.06)
Depression −0.34 (−0.95 to 0.28) 0.19 (−0.60 to 0.98) 0.51 (−0.62 to 1.61)
World Health Organisation Quality of Life
Physical health −0.15 (−0.76 to 0.46) −0.14 (−0.93 to 0.65) −1.18 (−2.35 to 0.03)
Psychological Health −0.07 (−0.68 to 0.55) −0.13 (−0.92 to 0.66) −0.41 (−1.51 to 0.71)
Social relationships 0.33 (−0.29 to 0.94) −0.10 (−0.89 to 0.69) −0.06 (−1.15 to 1.04)
Environment −0.45 (−1.07 to 0.17) −0.37 (−1.17 to 0.43) −0.28 (−1.37 to 0.83)
Global Assessment of Functioning
Total score −0.27 (−0.88 to 0.35) −0.07 (−0.86 to 0.72) −0.44 (−1.52 to 0.65)
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Health economic analysis
Conclusions regarding service use are tentative due to
the very small numbers with full data. Use of community
services appears to be higher in the SSCM-ED group,
but admissions were more likely in the MBT-ED group.
Similarly, it is difficult to use the cost data to draw
conclusions. Over 18 months follow-up, costs in the
MBT-ED group are, on average, more than £3000 higher
than in the SSCM-ED group. It appears that this is
predominantly due to the higher cost of the MBT inter-
vention. The difference in cost was not statistically
significant.
EQ-5D scores are generally similar between rando-
mised groups, and there is a slightly higher quality-
adjusted life years (QALY) score in the MBT-ED group,
but this may be due to the small numbers for whom it
was possible to calculate a QALY.
Discussion
Main results of the trial
The NOURISHED project is a study of two novel ther-
apies, MBT-ED and SSCM-ED, in patients with EDs and
symptoms of BPD. This study has been reported in
accordance with CONSORT guidelines (see Additional
file 2). An unusually high drop-out rate makes any
conclusions about effectiveness tentative. The study
was well designed and prepared by a large group of
collaborators with the active support of a highly
regarded Clinical Trials Unit. In spite of this, recruit-
ment was difficult and maintenance of patients in long-
term treatment and follow-up problematic. The most
significant result of the study was to demonstrate the
difficulties encountered in recruiting, treating and
retaining participants in the trial in a very complex
population.
Participants who stayed in the trial, irrespective of
treatment, showed significant clinical improvement in
both ED and BPD symptoms, although, because of the
drop-out rate, the significance of this finding remains
uncertain. Treatment trials for bulimia nervosa using
CBT report the following changes in EDE global score
between baseline and end of treatment: 1.1 [31], 1.6 [29]
and 1.9 [32] using CBT-E, and 1.4 [33] using guided
self-help. In our study the EDE global score change at
18 months was 1.2 for MBT-ED and 0.5 for SSCM-ED.
Treatment trials for BPD which use the ZAN-BPD are
few, but McMain et al. [34] report a reduction of 7.6
points using dialectical behaviour therapy. In our study
the mean reduction in ZAN-BPD for both arms of the
trial was 8.8 at 18 months.
Two of the EDE subscales, Shape Concern and Weight
Concern, showed significantly lower scores for the
MBT-ED compared to SSCM-ED at 18 months —
differences that were also detectable at 12 months. This
result needs to be interpreted with caution, due to drop-
outs. If reliable, it could indicate that the treatment
model of MBT-ED may have been superior to SSCM-
ED. However, it could be an effect of therapy ’dose’, as
MBT-ED provided four to five times the number of
treatment hours compared to SSCM-ED. In the study,
participants allocated to MBT-ED did have more therapy
hours than those allocated to SSCM-ED, with 47.1 % of
the former attending at least 50 % of individual and
group sessions, compared to 37.1 % of the latter.
Fig. 2 Unadjusted mean EDE scores for the whole trial sample for all post randomisation time points and baseline. Lowest score is best. Error
bars show standard error
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With regard to feasibility, any future trial must take
into account the following:
1. Training for MBT-ED introduced significant
delay and should precede the beginning of the
trial so that adequate numbers of therapists are
available.
2. There was a significant reduction in numbers of
participants returning for follow-up assessment.
Drop-out from the trial
Drop-out can refer to withdrawal from therapy or failure
to attend research assessments. The proportion of par-
ticipants not meeting our criterion of 50 % attendance at
therapy was 52.9 % for MBT-ED and 62.9 % for SSCM-
ED (a non-significant difference). Regarding research
assessments, the CONSORT diagram (Fig. 1) shows a
steady decline in attendance with 70.6 % non-attendance
in the MBT-ED group at 18 months, compared to
85.3 % for SSCM-ED, also a non-significant difference.
Hence, there was evidence that participants withdrew
from both therapy and research assessment. The causes
are not immediately apparent. We found evidence that
participants who scored highly on the neuroticism scale
of the BFI and those who were current smokers were
more likely to drop out. This may suggest that more
anxious participants may have found the trial too stress-
ful. We were aware that some participants (15 %) had
moved to different parts of the country. The EDE
showed that the population was of high severity, with a
mean level of EDE global score of 4.35 (SD 0.94, n = 68).
Compared to a population of patients with bulimia ner-
vosa [29] in which the global EDQ score was 3.79, our
patients scored substantially higher. The ZAN-BPD
results (mean 16.12 (SD 6.33) 95 % CI 14.62–17.62) were
somewhat higher than the mean found in patients with
BPD reported by Zanarini et al. [35], in which study sub-
jects had a mean total score of around 11.5. The instabil-
ity of participants with BPD may be a significant factor
contributing to the high drop-out from treatment.
In previous comparable trials, drop-out varies. There
is no previous report of an RCT for participants with
both EDs and BPD. However, in trials for borderline
participants, drop-out rates, albeit variously defined, are
reported as 50 % drop-out from therapy and 17 % loss to
follow-up [36], 39 % drop-out from therapy and assess-
ment [37], 43 % drop-out, including 19 % before treatment
started [38] and 26 % drop-out [2]. For RCTs with partici-
pants suffering from EDs, the drop-out rate ranges from
15–70 % [39, 40]. Both EDs and BPD have serious phys-
ical, psychological and social morbidity, reflected in the
very high baseline levels of eating disorder, borderline and
general psychiatric disturbance that we found. It is quite
likely that the combination of the two sets of conditions
resulted in a level of overall disturbance which affected
compliance and increased drop-out.
Participants allocated to SSCM-ED were significantly
more likely to drop out before the start of therapy than
those allocated to MBT-ED. However, participants who
dropped out at different times during therapy did not
cite dissatisfaction with therapy in one approach signifi-
cantly more than the other. Walsh et al. [41], in a study
of guided self-help and medication in bulimia nervosa,
found an overall drop-out rate of 70 %, amongst whom
one-third cited problems with therapy as the reason,
compared to one-fifth in our study. In a study of cogni-
tive behaviour therapy and medication in anorexia ner-
vosa [40], 46 % of participants dropped out and a further
17 % were withdrawn due to treatment failure. The only
correlate of drop-out found in that study was high self-
esteem, which was associated with fewer drop-outs. In a
study of CBT and dietary counselling in anorexia ner-
vosa [42], all ten participants in the Dietary Counselling
group dropped out of treatment, compared to just one
in the CBT group. The reasons for the drop-out are un-
certain, but the result was that dietary counselling alone
was not regarded as a useful treatment on its own in an-
orexia nervosa, a view also reflected in the NICE guide-
lines for eating disorders [43].
Other difficulties encountered in the present study in-
cluded service and staff changes which affected the trial
and which can be expected in an NHS service. However,
they were particularly severe in our study, with emigration
of two Principal Investigators and limitations on recruit-
ment and treatment capacity due to service changes.
Positive outcomes of the trial
Two new forms of therapy for patients with EDs were
developed. MBT was adapted for use in an eating disor-
dered population (MBT-ED), and this has led to the im-
plementation of MBT-ED in the clinical services taking
part in the trial.
SSCM-ED was expanded from the original therapy de-
signed for patients with anorexia nervosa. SSCM-ED can
be used for any eating disorder, and this has also been im-
plemented in the clinical services participating in the trial.
The clinical field of EDs has, therefore, benefited from
the trial, and as more therapists become competent in
the two approaches, a larger randomised controlled trial
will be more feasible.
We were fortunate to have a group of users and carers
as part of the research team. Their main contribution was
in the design of the study and the information sheets, their
participation in Trial Oversight Committees and their help
on research staff appointment committees. However, in
spite of these important contributions, they felt under-
used in the trial, and this issue should be reviewed in ad-
vance of any future trial. Participants knew that they could
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see one of the user consultants, and families were told that
they could see the carer consultant if they had concerns,
but this facility was not used.
Limitations
Developing two new versions of established therapies
and testing them in a multi-centre RCT in a population
of high morbidity and complexity within 3–4 years was
problematic. The therapies are now developed with
some indication of good clinical outcomes, so the chal-
lenge of a new study would be to maintain participants
in the research for at least 18 months. Craig et al. [44]
clearly advise extensive piloting and preparation before
embarking on a full RCT, and, with the experience of
this study, we fully endorse that advice.
The problem raised by the present study is how to
maintain a group of patients with very challenging symp-
toms who are increasingly seen in clinical practice in a
research trial for long enough to determine efficacy. In
the present study, the Chief Investigator (PR) was not
directing the overall clinical management of the partici-
pants. This is in contrast to a randomised controlled trial of
MBT in BPD [45] in which treatment and research were
carried out in a single psychotherapy unit, directed by the
Chief Investigator. In that study the drop-out from therapy
was 12 %, and the different model of clinical management
may have contributed to that low rate of drop-out.
Conclusion
Over the first 18 months, in participants remaining in
the study, there were improvements in ED and BPD
symptoms in the whole group under study, and MBT-
ED seemed to be more effective in addressing body
image disturbance in EDs complicated by BPD.
The best outcome for patients with bulimia nervosa,
the condition experienced by most of our participants, is
associated with cognitive behaviour therapy [24]. How-
ever, therapy for patients with both EDs and BPD has
not been evaluated in a randomised trial, and there are
indications that this group would have a less satisfactory
clinical outcome [1]. We suggest that a further feasibility
study be mounted in order to establish how MBT-ED,
perhaps with a comparison therapy, could be provided
to patients with both Eating disorders and borderline
personality disorder symptoms in a way that is accept-
able to those patients.
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